Background: In today's healthcare environment, public health resources are scarce. Thus, in terventions to improve the public's health must be rigorously evaluated to ensure that they make the best use of available resources.
INTRODUCTION
Successful evaluations will be built into the pro gram design; will be multifaceted, incorporating HE SCARCITY OF PUBLIC HEALTH RESOURCES in to-both quantitative and qualitative methods; will day's healthcare environment requires that assess both process and outcome measures; and interventions to improve the public's health be will engage stakeholders to ensure utility of re evaluated using rigorous scientific methods. Pub-sults. Well-planned evaluations can lead to less lic health interventions that cannot demonstrate burdensome yet more effective assessment and effective use of resources may not be imple-better program performance and can increase the mented. Thus, evaluation designs must recognize knowledge base for health promotion practice. and integrate the requirements of funding agents,
The Centers for Disease Control and Prevention ensure that intervention benefits can be accu-(CDC) provides a general framework for program rately measured and conveyed, and ensure that evaluation. 1 This paper presents additional detail areas for improvement can be continuously iden-on several key evaluation areas within CDC's tified. Public health interventions are complex, framework. We emphasize how to apply the eval and therefore proper evaluation is a challenge. uation to demonstration programs, which require 1 RTI International, Health, Social and Economics Research, Research Triangle Park, North Carolina. 2 Centers for Disease Control and Prevention, Division of Nutrition and Physical Activity, Atlanta, Georgia. Funding for this work was provided by the Centers for Disease Control and Prevention under contract number 200-97-0621. The views expressed in this paper are not necessarily those of the CDC or RTI International. more detailed analyses than do fully funded pro grams and often necessitate collection of addi tional data. We focus primarily on analysis of the effectiveness and cost-effectiveness of the CDC's Well-Integrated Screening and Evaluation of Wo men Across the Nation (WISEWOMAN) pro gram, an ongoing set of screening and lifestyle in tervention demonstration projects aimed at reducing cardiovascular disease (CVD) risk fac tors among low-income, underinsured and unin sured women in 14 states and tribes. 2 Specific ex amples are presented of how effectiveness and cost-effectiveness analyses are being incorporated into the WISEWOMAN demonstration program. We first provide an overview of the WISE WOMAN comprehensive evaluation plan.
WISEWOMAN COMPREHENSIVE EVALUATION PLAN
Because no single evaluation technique can ad dress evaluations of process measures as well as intermediate and ultimate outcomes, different eval uation approaches should be coordinated to form a comprehensive evaluation plan. Several evalua tion approaches make up the WISEWOMAN eval uation plan, which is concerned with whether the program is successful at efficiently improving CVD risk factors among participants and at meeting other program goals and seeks to learn how and why specific aspects of the program influence its success. The WISEWOMAN evaluation plan doc uments the accomplishments of the program thus far; supports ongoing quality assurance; ensures implementation of interventions with fidelity to design, measuring short-term, intermediate, and long-term program outcomes; tests new ap proaches and innovations; and discerns best and promising practices that can be used for program improvement. The conceptual framework of the WISEWOMAN program (Fig. 1) illustrates the pro gram components and opportunities for evaluation questions. A draft evaluation matrix for WISE WOMAN is shown in Table 1 . The matrix includes structural and process determinants and shortterm, intermediate, and long-term outcomes across individual, organizational, and community pro gram levels. The matrix makes clear the complex ity of the program and the multitude of evaluation opportunities.
Limited resources require that evaluation of WISEWOMAN take a phased approach. The fo-
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cus of the early phase is on evaluating program feasibility and acceptability and developing the infrastructure required to evaluate program ef fectiveness and cost-effectiveness. The next two sections discuss the effectiveness and cost-effec tiveness evaluation approaches of WISEWOMAN. The focus of the second phase is on evaluating best practices, which is addressed in another pa per in this Supplement. 3 
Effectiveness evaluation
Although a program's effectiveness cannot be fully assessed until the participants have com pleted the intervention, effectiveness evaluation must be designed before program implementa tion to ensure that the necessary preintervention and postintervention data are collected. Thus, the first task is to determine which data should be collected. The data must be detailed enough to answer key questions concerning intervention benefits but not overly burdensome for the re spondents or those implementing the interven tion. For WISEWOMAN, participating local pro jects and the CDC have developed a standard set of minimum data elements (MDEs) that must be collected for all participants at baseline and at the end of 1 year (Appendix). Projects submit the MDEs to the CDC twice annually. Although most projects also collect additional data and do their own evaluation, the MDE data are consolidated across programs, allowing for a more in-depth analysis of the impact of WISEWOMAN than would be possible with data from a single pro gram only.
The MDEs selected for WISEWOMAN focus on specific risk factors (e.g., blood pressure, choles terol, and smoking rates). Many are identical to those captured by the CDC's Behavioral Risk Fac tor Surveillance System (BRFSS). 4 This has sim plified the MDE pretesting and validation process and allows for state-level comparisons of CVD risk among WISEWOMAN participants and wo men in the general population.
The WISEWOMAN MDEs can be combined into a summary measure that assesses overall CVD risk: the change in 10-year probability of coronary heart disease (CHD) over the 12-month period following enrollment. Summary measures are important because they allow evaluators to assess the benefits of an intervention by using a single measure that can be easily conveyed to pol icymakers. Ideally, a summary measure is broad EVALUATION OF PUBLIC HEALTH PROGRAMS enough to allow for comparisons with similar in terventions but narrow enough that an effective intervention will show statistically significant im provements given the available sample size. As a general rule, it becomes more difficult to accu rately quantify a summary measure and a greater number of assumptions are required as the gen eralizability of the measure increases. The WISE WOMAN summary measure was chosen because it assesses overall reduction in CVD risk and is relatively easy to calculate on the basis of exist ing risk-scoring algorithms. 5, 6 Summary measures assess changes in health status among those who receive an intervention. To determine if the changes are a direct result of the intervention, however, the participants' health status in the absence of the intervention must be determined. The standard approach is to compare the change in participants' health with that of a similar control group. For WISEWOMAN, how ever, this clinical trial approach is complicated by the lack of a true control group. In WISE WOMAN, ethical concerns mandate that all en rolled women, including those in control groups, receive the results of their baseline screening ex amination as well as the usual standard of care.
Women who have dangerous CVD risk factor measures are referred to a physician and may re ceive education, medication, or additional followup care. Because women in the control group are provided with information and services, they may show different results than if they had re ceived no services at all. As a result, without additional information or assumptions, WISE WOMAN evaluations can compare the effective ness (and cost-effectiveness) of screening plus in terventions with that of screening alone but cannot compare the effectiveness of the interven tions with a baseline of no intervention.
In some instances, evaluators may be able to iden tify a suitable control group from outside the inter vention. For example, WISEWOMAN projects have assessed general trends in CVD risk factors by us ing the CDC's BRFSS data. When incorporating data from outside sources, however, evaluators must consider the possibility that differences in sample se lection and other potential biases may confound the comparisons. For example, because both the BRFSS and WISEWOMAN collect limited demographic data, we cannot be sure that the women in these two groups do not differ in unobservable characteristics that might affect their risk of CVD. An alternative approach to using supplemen tal data is to assume that in the absence of the in tervention, risk factors remain unchanged. This approach requires interventions to show im provements in risk factors to be deemed success ful. For example, suppose that women enrolled in WISEWOMAN showed no net change in 10 year CHD risk during their enrollment period. Given this result, one might assume that WISE WOMAN participation had no effect on CHD risk, but if this result occurred in the presence of an increase in CHD risk in the general popula tion, then the intervention could be credited with avoiding these risks. However, if there had been a decrease in CHD risk in the general population, this could indicate that participation in the inter vention actually increased CHD risk.
Experience has shown that it is often difficult to show statistically significant differences in a broad or comparable summary measure. For ex ample, in an early analysis of the Massachusetts WISEWOMAN project, the difference in the sum mary measure was not statistically significant even though the screening and intervention group showed greater reductions in CHD risk than did the group that received screening only. 7 An early analysis of the North Carolina WISE WOMAN project showed the same result. 8 Thus, in addition to the summary effectiveness mea sure, evaluations should include supplemental indicators of effectiveness, such as changes in other outcome measures and behavior. In addi tion to changes in CHD risk, WISEWOMAN evaluates changes in blood pressure, cholesterol, smoking status, healthy eating indexes, and phys ical activity. Significant improvements in supple mental measures will provide additional evi dence of the program's benefits.
Cost-effectiveness evaluation
An effective intervention is a necessary but not sufficient condition for justifying the expansion of a demonstration program. An additional re quirement is that a given intervention justify the use of scarce public health resources. Cost-effec tiveness analysis, defined as the costs required to yield a specific, comparable outcome, addresses this issue and can play an important role in de termining funding priorities.
When constructing a cost-effectiveness ratio, it is important to consider the question the ratio is intended to answer. For example, the summary measure of effectiveness for WISEWOMAN is the 10-year probability of CHD. For WISEWOMAN projects that enroll a comparison group, the costeffectiveness analysis addresses the incremental cost-effectiveness of screening plus intervention compared with screening alone and can be cal culated as follows:
Cost-effectiveness ratio ϭ
where CG represents the control group (screening only) and IG represents the intervention group (screening plus intervention). A cost-effectiveness analysis of the early version of the Massachusetts WISEWOMAN project found that it cost an addi tional $637 to achieve a (statistically insignificant) 1-percentage point larger decrease in the 10-year probability of CHD in the screening plus inter vention group than in the screening only group. 7 Incremental change for either group (screening or screening plus intervention) can be calculated by assuming that CHD risk is flat for nonpartic ipants or by estimating changes in CHD risk for nonparticipants by using BRFSS or similar data. Because the cost of providing no screening or in tervention is zero, a cost-effectiveness ratio that compares screening, or screening plus interven tion, with no intervention can be easily calculated by using the cost-effectiveness formula. This ra tio can then be compared with the cost-effective ness ratios of similar interventions to determine a program's relative cost-effectiveness.
Although the formula for determining cost-ef fectiveness is simple, deciding which costs to in clude and accurately quantifying them often is difficult. Issues related to effectiveness focus pri marily on identifying an appropriate measure of effectiveness. The primary issue concerning costs centers on which costs to include and how to quantify them. In general, cost-effectiveness analyses should include opportunity costs of par ticipation, defined as the opportunities foregone as a result of participating in intervention-related activities; direct dollar outlays associated with the implementation; and the dollar value of program resources not reflected in program budgets, such as volunteer labor and on-hand or donated facil ities and equipment. The total of these costs, termed societal costs, is required for proper costeffectiveness analysis. 9 Although direct dollar outlays are readily available from program budgets and the valua tion of free and on-hand resources can be easily estimated, measurement of participant opportu nity costs is more complicated. As is the case with many interventions, participation does not end when a woman leaves an intervention session. For WISEWOMAN, it would be extremely ex pensive to quantify all the additional time that women spend performing related activities, such as reading food labels, cooking healthier meals, and walking. For demonstration projects, it may be appropriate to ignore opportunity costs in the demonstration phase and to simply explore how many additional resources (regardless of payer) would be required to fund an expansion of the existing intervention. Only when an intervention proves to be effective should additional resources be dedicated to quantifying costs from a broader societal perspective.
Quantifying incremental costs, which are the relevant costs included in cost-effectiveness ra tios, is not straightforward. Some evaluators make the simple assumption that if the size of the program were doubled, a doubling of the origi nal budget would be required to fund the ex pansion. However, this is unlikely to be the case. The cost of expanding a successful demonstration project is generally less than the cost of provid ing the original demonstration because many ac tivities do not need to be repeated. Economists define these one-time costs as sunk costs. For ex ample, WISEWOMAN demonstration projects spend substantial resources developing nutrition and physical activity interventions, designing forms, developing training programs, and con ducting other activities that would not need to be repeated if the intervention were expanded. These one-time costs should not be included in the numerator of a cost-effectiveness ratio that is being used to consider whether to expand a demonstration project. On the other hand, most successful interventions rely on existing infra structure and collaboration with other agencies to deliver some services. For example, some WISE WOMAN projects refer participants to existing smoking cessation classes. Although the cost may not be funded out of the WISEWOMAN budget, the classes represent real expenditures that should be included in the cost-effectiveness analysis.
In many cases, it is not obvious whether cer tain costs should be included. If a woman enrolls in WISEWOMAN and is subsequently found to have heart disease requiring major surgery, it is
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unclear if the surgery and follow-up care costs should be included in the societal cost of the demonstration project. One solution is to exclude from the analysis any costs that are not expected to recur. Stated another way, if one individual has a high-cost random experience (e.g., a medical in tervention), the costs can be excluded, but if many individuals have the same experience, the occur rence ceases to be random and the costs need to be considered.
Once evaluators have identified appropriate project costs, they must determine how to mea sure them. A straightforward approach is to mea sure costs at the primary activity level. The ac tivity-based approach assesses how much it costs to provide each primary activity and identifies the components of these costs (including sunk costs). If implemented correctly, this approach can capture most project-related costs and facili tate the cost-effectiveness analysis. For example, WISEWOMAN has three primary activities-out reach and follow-up, screening, and interven tion-and a catchall activity called administra tion. Outreach and follow-up consist of activities associated with enrolling women and promoting retention. Screening includes activities associated with collecting medical information and commu nicating assessment results. Intervention includes activities associated with providing the nutrition and physical activity interventions. Administra tion includes all remaining activities that cannot be allocated to one of the three primary activities. For the Massachusetts evaluation noted previ ously, the costs associated with all three activities averaged $603 per participant.
Within each activity category, there are three types of costs (that may or may not be sunk costs), (1) (noncontract) labor costs, (2) contracted service costs; and (3) costs associated with facilities, ma terials, and supplies. Noncontract labor costs con sist of the dollar value (salary plus benefits) of the time that employees spend performing demon stration activities. These costs should be measured (e.g., via time sheets) for all individuals whose la bor is not captured through another mechanism (i.e., billed directly to the project). Contracted ser vice costs include costs for demonstration activi ties provided by outside entities. For example, in most states, physicians who perform WISE WOMAN screenings submit a bill for services ren dered. Documenting contracted service costs is straightforward but requires sites to keep track of the bills associated with contracted services and to map the bills to the appropriate activity. Finally, EVALUATION OF PUBLIC HEALTH PROGRAMS the costs of facilities, materials, and supplies in clude costs for promotional materials and materi als or supplies purchased to support intervention activities (e.g., cookbooks and pedometers).
DISCUSSION
Effectiveness and cost-effectiveness analyses are two important aspects of a comprehensive evaluation. It is these outcome measures that may be the most persuasive to stakeholders and poli cymakers. However, these measures do not iden tify intervention strengths and weaknesses, and it is often difficult to show statistical significance in the summary outcome measures used in costeffectiveness ratios, even for interventions that are truly effective. Also, cost-effectiveness ratios are not the only measures that policymakers con sider. Thus, cost-effectiveness analysis should be only one component of a comprehensive evalua tion. Before summary outcomes can be generated, an evaluation must assess the intervention design and implementation processes to ensure program success. Before outcome measures can be fully understood and interpreted, an evaluation must assess intermediate outcomes and other effects of the evaluation. The complexity and context-de pendent nature of health promotion programs ne cessitate that cost-effectiveness analysis be im plemented in conjunction with other evaluation techniques, including process evaluation and ad ditional outcome evaluation.
In this paper, we have described the effective ness and cost-effectiveness evaluation methods for WISEWOMAN because answering questions re lated to effectiveness and cost-effectiveness is a pri ority in an era in which public health interventions must be able to convincingly prove their worth to maintain funding. However, WISEWOMAN in corporates many comprehensive evaluation ele ments in addition to the effectiveness and costeffectiveness analyses. These include process, structural, and supplemental outcome measures used to assess design, implementation, and ef fects at individual, organizational, and commu nity program levels.
Process evaluation focuses on the operation of a program-what is working and what is not-and has been defined as relating to assurance of qual ity of practice or as an assessment of how a pro gram is implemented. 10, 11 Process evaluation can assess how a program is structured and imple mented and what activities are provided, under what conditions, by whom, and for whom. Critical process indicators collected by WISEWOMAN in clude how long it takes to fully field the interven tion, enrollment rates, participant dropout rates, staff turnover, and allocation of budgetary funds. Process indicators can also be qualitative, intended to provide a detailed understanding of both the in ternal dynamics of a program and its interaction and relation with the environment. For example, WISEWOMAN projects are required to describe instances of community engagement, such as the use of existing community resources in the inter vention, both for assessing intervention design and for ensuring implementation quality and effi ciency. Process measures may alert project admin istrators and evaluators to problems in implemen tation, problems in recruitment, or intervention design flaws that could jeopardize the ultimate suc cess of an intervention.
The WISEWOMAN evaluation plan also in corporates additional outcome measures. These short-term, intermediate, or long-term outcome measures evaluate intervention effects not cap tured by the summary outcome measure. These measures can provide earlier or more descriptive evidence of intervention effects than is captured by the summary outcome measure. Impact eval uation can provide important individual-level data, such as tracking participants' precursors to change. Some WISEWOMAN projects measure changes in knowledge, attitudes, and beliefs (KAB) and in self-efficacy, which are expected to precede any lifestyle or behavior changes caused by the intervention. Other projects include par ticipants' stage of change, in which the partici pants are classified within a process of change de lineated into a series of sequential stages. 12 Not only can stages of change be an effective tool for tailoring interventions to each individual's readi ness for change, but they also can detect early ev idence of change or identify barriers to change. 13 Impact measures included in the WISEWOMAN MDEs include changes in nutrition, physical ac tivity, and smoking behavior. In addition to in dividual-level impacts, the evaluation will also attempt to document impacts on organizations and communities because these can constitute a major, lasting achievement of health intervention projects. 14 Thus, a goal of WISEWOMAN is to en courage improvement in efficiency and effective ness among the sponsoring agencies and com munity partners and to improve provider norms. Community impacts can constitute effects of even greater scope than organizational change. Later stages of the WISEWOMAN evaluation will as sess changes in overall population health and im pacts on community health delivery systems, resources, and the environment using such mea sures as community-level indicators. 15, 16 The evaluation techniques briefly described here identify those aspects of a program that are more or less successful at effecting behavior change, and why. In the context of the early phases of WISEWOMAN program evaluation, they serve to bolster the ultimate products of the evaluation: the effectiveness and cost-effectiveness analyses. Process evaluation can help ensure that an inter vention operates as it should to produce the de sired outcomes by facilitating improvement and providing an improved understanding of how the intervention functions. Impact evaluation is used to document the early effects of an intervention as well as outcomes that may not be captured in the summary outcome measure selected for the costeffectiveness analysis. It is the cost-effectiveness outcome evaluation, however, that will likely be the ultimate measure of a program's worth. The outcome evaluation must correctly capture the most important effect of the intervention in a man ner that is accurate while still being comparable to the outcomes of other health interventions. The outcome evaluation must also accurately measure the resources required to achieve this outcome. A truly comprehensive evaluation will provide ac curate, unbiased information to ensure that an in tervention operates to its full potential and to appraise and communicate the intervention's eventual level of success. Ultimately, the evalua tion will serve as the basis for determining whether to expand a demonstration project and how to tai lor the intervention to improve health among par ticipants and other affected parties.
